

EQA round: CSFC1/23 - Cerebrospinal Fluid Cytology

Deadline: 28.3.2023

Setup: all data

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVE = consensus of the experts

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

| Test Sample Group | Frequency of the results | | | | Success | | |
|---|--------------------------|------------------|-------------------------|--|------------------|------------------|-------------------------|
| | AV | N _{tot} | N _{rel} [%] | Result | N _{eva} | N _{suc} | S _{rel} [%] |
| (416) Morphological identification of elements | | 62 | | | 62 | 60 | 97 |
| Photo 1 | | 62 | | | 62 | 62 | 100 |
| All results | CVE >>> | 62 | 100 | Cell tumorous | | | |
| Photo 2 | | 62 | | | 62 | 60 | 97 |
| All results | CVE >>> | 27 | 44 | Lymphocyte non-activated | | | |
| | CVE >>> | 33 | 53 | Lymphocyte activated - lymphoid cell | | | |
| | | 2 | 3,2 | Plasmocyte | | | |
| (417) Syndromological classification | | 61 | | | 61 | 57 | 93 |
| Photo 1 | | 61 | | | 61 | 60 | 98 |
| All results | | 1 | 1,6 | Tumorous oligocytosis | | | |
| | CVE >>> | 60 | 98 | Tumorous pleocytosis | | | |
| Photo 2 | | 61 | | | 61 | 57 | 93 |
| All results | | 4 | 6,6 | Lymphocytic oligocytosis | | | |
| | CVE >>> | 57 | 93 | Lymphocytic pleocytosis | | | |
| (418) Etiological diagnosis | | 61 | | | 61 | 58 | 95 |
| Photo 1 | | 61 | | | 61 | 61 | 100 |
| All results | CVE >>> | 61 | 100 | Tumorous impairment of CNS | | | |
| Photo 2 | | 61 | | | 61 | 58 | 95 |
| All results | | 2 | 3,3 | Normal cytological finding | | | |
| | CVE >>> | 45 | 74 | Picture of serous inflammation | | | |
| | | 1 | 1,6 | Tissue destruction | | | |
| | > | 13 | 21 | Picture of non-specific (reactive) changes | | | |